查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602214

疫苗市場：按類型、技術類型、給藥途徑、適應症、年齡層分類 - 2025-2030 年全球預測

Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines), Route of administration, Indication, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年疫苗市值為689.2億美元，預計2024年將達到741.6億美元，複合年成長率為7.70%，到2030年將達到1158.9億美元。

疫苗是提供針對特定疾病的免疫力的生物製藥，在預防保健中扮演重要角色。疫苗市場涉及廣泛的領域，包括預防疾病的預防性疫苗和治療疾病的治療性疫苗。 COVID-19 大流行等全球健康挑戰加劇了對疫苗的需求，增加了對 mRNA 疫苗等新疫苗技術的需求。最終用途包括醫院、診所和研究機構。一個關鍵的成長要素是對全球免疫計畫的認知和投資的提高，並由各國政府和非政府組織進一步推動。技術進步，加上研發資金的增加，為相關人員在疫苗輸送機制和穩定性方面進行創新創造了有利可圖的機會。然而，嚴格的監管政策、不斷上升的研發成本和疫苗猶豫等挑戰可能會阻礙市場成長。此外，開發中國家的供應鏈中斷和准入不平等也構成了重大限制。有前景的創新和研究領域包括個人化技術、輔助技術和無針給藥系統，這些技術有可能提高療效和患者依從性。它還表明製藥公司、科技公司和公共衛生機構之間的合作可以加速突破。尋找數位健康解決方案來簡化疫苗分發和追蹤結果代表著開拓的潛力。儘管存在競爭格局，但不斷變化的治療需求和全球公共衛生安全的需求正在培養特定市場的擴張。總體而言，疫苗市場準備應對可用性和可負擔性的挑戰，同時利用個人化免疫療法和區塊鏈等新機會來提高供應鏈透明度的技術創新，預計將持續成長。

主要市場統計
基準年[2023] 689.2億美元
預測年份 [2024] 741.6億美元
預測年份 [2030] 1158.9億美元
複合年成長率（%） 7.70%

市場動態：揭示快速發展的疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 人們越來越認知到新興感染疾病的爆發和疫苗接種的好處
    • 增加政府資金鼓勵疫苗開發
  • 市場限制因素
    • 高開發成本和產品召回問題
  • 市場機會
    • 生技公司開發創新疫苗的投資激增
    • 透過建立公私夥伴關係改善疫苗分配
  • 市場挑戰
    • 疫苗核准過程的長度和相關的疫苗副作用

波特的五力：駕馭疫苗市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對疫苗市場的影響

外部宏觀環境因素對疫苗市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解疫苗市場的競爭狀況

對疫苗市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣疫苗市場供應商績效評估

FPNV定位矩陣是評估疫苗市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人們越來越認知到新感染疾病的傳播和疫苗接種的好處
      • 增加政府資金加速疫苗開發
    • 抑制因素
      • 開發成本上升和產品召回問題
    • 機會
      • 生技公司開發創新疫苗的投資激增
      • 公私合營的興起改善了疫苗的分配
    • 任務
      • 漫長的疫苗核准過程和相關的疫苗副作用
  • 市場區隔分析
    • 類型：接觸不同株時，多效價疫苗至關重要
    • 技術類型：快速發展和高效提高了mRNA疫苗的重要性
    • 給藥途徑：由於強烈的免疫反應，優選肌內（IM）和皮下（SC）途徑。
    • 適應症：傳播流感疫苗以預防季節性流感流行
    • 年齡層：老年人和慢性病患者需要有效接種疫苗
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章疫苗市場：依類型

  • 單價疫苗
  • 多效價疫苗

第7章疫苗市場：依技術類型

  • 無效疫苗
  • 減毒活疫苗
  • 傳訊RNA(mRNA) 疫苗
  • 次單元、重組、多醣體和結合疫苗
  • 類毒素疫苗
  • 病毒載體疫苗

第8章疫苗市場：依給藥途徑分類

  • 肌肉內和皮下
  • 口服

第9章 疫苗市場：依適應症分類

  • b型流感嗜血桿菌
  • 甲型肝炎和B型肝炎
  • 人類乳突病毒
  • 麻疹、腮腺炎、德國麻疹
  • 病菌感染感染
  • 肺炎鏈球菌感染
  • 脊髓灰質炎
  • 狂犬病
  • 輪狀病毒
  • 帶狀皰疹
  • 破傷風、白喉、百日咳
  • 水痘

第10章疫苗市場：依年齡層

  • 成人
  • 小兒科

第11章美洲疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Mankind Pharma 20 億美元收購 Bharat Serums and Vaccines 擴大疫苗產能
    • 賽諾菲和 Novavax 合作共同商業化新的 COVID-19 疫苗並開發流感/冠狀病毒聯合疫苗
    • CureVac 和 MD 安德森合作開發以 mRNA 為基礎的癌症疫苗，為先進癌症治療鋪路
    • Bharat Biotech 與 Bilthoven Biologicals 合作，透過提高 OPV 產量加強全球根除脊髓灰質炎工作
    • 武田製藥合作改善全球登革熱疫苗的可近性，瞄準高影響地區
    • Astra Zeneca收購生物技術公司 Icosavax 以加強疫苗能力
    • 印度血清研究所與 CEPI 合作，改善疫情期間全球疫苗的獲取
    • GSK與智飛合作在中國獨家經銷帶狀皰疹疫苗Shingrix，旨在改善公眾健康和疫苗可及性
    • 楊森和賽諾菲合作開發疫苗計劃，以滿足未滿足的醫療需求
    • 全球努力加強大流行防範，為 Genova 的自放大 mRNA 疫苗（針對 X 型感染疾病）提供資金
    • 巴伐利亞北歐公司在美國推出 Mpox 疫苗，促進預防保健和市場創新
  • 戰略分析和建議
    • Astra Zeneca
    • 輝瑞公司
    • GlaxoSmithKline Plc
    • 默克公司
    • 賽諾菲公司

公司名單

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Biological E. Limited
  • BioNTech SE
  • Blue Lake Biotechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac NV
  • Daiichi Sankyo Company, Limited.
  • Emergent BioSolutions Inc.
  • Gennova Biopharmaceuticals Limited
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Versatope Therapeutics
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA0513E

The Vaccines Market was valued at USD 68.92 billion in 2023, expected to reach USD 74.16 billion in 2024, and is projected to grow at a CAGR of 7.70%, to USD 115.89 billion by 2030.

Vaccines are biological preparations that provide immunity against specific diseases and are critical in preventive healthcare. The vaccine market encompasses a broad spectrum including prophylactic vaccines for disease prevention and therapeutic vaccines for disease treatment. The necessity of vaccines has been underscored by global health challenges such as the COVID-19 pandemic, increasing the demand for novel vaccine technologies like mRNA vaccines. Applications extend beyond infectious diseases to areas such as cancer, allergies, and autoimmune disorders, while end-use sectors include hospitals, clinics, and research institutes. A significant growth factor is the increased awareness and investments in immunization programs worldwide, further propelled by government and non-governmental organizations. Technological advancements, coupled with expanding research and development funding, present lucrative opportunities for stakeholders to innovate in vaccine delivery mechanisms and stability. However, challenges such as stringent regulatory policies, high R&D costs, and vaccine hesitancy might impede market growth. Moreover, supply chain disruptions and inequitable access in developing countries represent substantial limitations. Promising areas for innovation and research include personalized vaccines, adjuvant technology, and needle-free delivery systems, which could enhance effectiveness and patient compliance. Insights indicate that collaboration between pharmaceutical companies, tech firms, and public health organizations can accelerate breakthroughs. Exploring digital health solutions for enhancing vaccine distribution efficiency and outcome tracking presents untapped potential. Despite the competitive landscape, the market's inherent expansion is nurtured by evolving therapeutic needs and the imperative for global public health security. Overall, the vaccine market holds promise for continuous growth, contingent upon addressing challenges of accessibility and affordability, while leveraging technological innovations to tap into emerging opportunities like personalized immunotherapy and blockchain for supply chain transparency.

KEY MARKET STATISTICS
Base Year [2023] USD 68.92 billion
Estimated Year [2024] USD 74.16 billion
Forecast Year [2030] USD 115.89 billion
CAGR (%) 7.70%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccines Market

The Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of new infectious diseases and increase in awareness about the benefits of vaccination
    • Increased government funding encouraging vaccine development
  • Market Restraints
    • High development costs and Issues over product recalls
  • Market Opportunities
    • Surge in investments by biotech companies for innovative vaccine development
    • Emerging collaborations between public and private sectors improve vaccine distribution
  • Market Challenges
    • Lengthy vaccine approval processes and associated side impacts of vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccines Market

A detailed market share analysis in the Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccines Market

A strategic analysis of the Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, BioNTech SE, Blue Lake Biotechnology, Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, CureVac N.V., Daiichi Sankyo Company, Limited., Emergent BioSolutions Inc., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Monovalent Vaccine and Multivalent Vaccine.
  • Based on Technology Type, market is studied across Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.
  • Based on Route of administration, market is studied across Intramuscular & Subcutaneous and Oral.
  • Based on Indication, market is studied across Haemophilus Influenzae Type b, Hepatitis A & Hepatitis B, Human Papillomavirus, Measles, Mumps, & Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rabies, Rotavirus, Shingles/Herpes Zoster, Tetanus, Diphtheria, & Pertussis, and Varicella.
  • Based on Age Group, market is studied across Adults and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of new infectious diseases and increase in awareness about the benefits of vaccination
      • 5.1.1.2. Increased government funding encouraging vaccine development
    • 5.1.2. Restraints
      • 5.1.2.1. High development costs and Issues over product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in investments by biotech companies for innovative vaccine development
      • 5.1.3.2. Emerging collaborations between public and private sectors improve vaccine distribution
    • 5.1.4. Challenges
      • 5.1.4.1. Lengthy vaccine approval processes and associated side impacts of vaccines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Critical need for Multivalent vaccines in case of exposure to various strains
    • 5.2.2. Technology Type: Growing significance of mRNA vaccines due to their rapid development and high efficacy
    • 5.2.3. Route of Administration: High preferences for intramuscular (IM) and subcutaneous (SC) routes owing to their strong immune response
    • 5.2.4. Indication: Widespread adoption of influenza vaccines for preventing seasonal flu outbreaks
    • 5.2.5. Age Group: Need for effective vaccination for the elderly and individuals with chronic health conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Monovalent Vaccine
  • 6.3. Multivalent Vaccine

7. Vaccines Market, by Technology Type

  • 7.1. Introduction
  • 7.2. Inactivated Vaccines
  • 7.3. Live-Attenuated Vaccines
  • 7.4. Messenger RNA (mRNA) Vaccines
  • 7.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
  • 7.6. Toxoid Vaccines
  • 7.7. Viral Vector Vaccines

8. Vaccines Market, by Route of administration

  • 8.1. Introduction
  • 8.2. Intramuscular & Subcutaneous
  • 8.3. Oral

9. Vaccines Market, by Indication

  • 9.1. Introduction
  • 9.2. Haemophilus Influenzae Type b
  • 9.3. Hepatitis A & Hepatitis B
  • 9.4. Human Papillomavirus
  • 9.5. Measles, Mumps, & Rubella
  • 9.6. Meningococcal Disease
  • 9.7. Pneumococcal Disease
  • 9.8. Polio
  • 9.9. Rabies
  • 9.10. Rotavirus
  • 9.11. Shingles/Herpes Zoster
  • 9.12. Tetanus, Diphtheria, & Pertussis
  • 9.13. Varicella

10. Vaccines Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Pediatric

11. Americas Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Mankind Pharma to Acquire Bharat Serums and Vaccines in USD 2 Billion Deal, Expanding Vaccine Production Capabilities
    • 14.3.2. Sanofi and Novavax Partner to Co-Commercialize New COVID-19 Vaccine and Develop Flu-COVID Combo Shot
    • 14.3.3. CureVac and MD Anderson Team Up to Develop mRNA-Based Cancer Vaccines, Paving the Way for Advanced Cancer Treatments
    • 14.3.4. Bharat Biotech and Bilthoven Biologicals Unite to Boost Global Polio Eradication Efforts with Enhanced OPV Production
    • 14.3.5. Takeda Forms Partnership to Boost Global Access to Dengue Vaccine, Targeting Hard-Hit Regions
    • 14.3.6. AstraZeneca Bolsters Vaccine Capabilities by Acquiring Biotechnology Firm Icosavax
    • 14.3.7. Serum Institute of India Partners with CEPI to Boost Global Vaccine Accessibility During Epidemics
    • 14.3.8. GSK Partners with Zhifei to Exclusively Distribute Shingles Vaccine Shingrix in China, Aiming to Enhance Public Health and Vaccine Access
    • 14.3.9. Janssen and Sanofi Join Forces to Develop Vaccine Program to Address Unmet Medical Needs
    • 14.3.10. Global Initiative Boosts Pandemic Preparedness with Funding for Gennova's Self-Amplifying mRNA Vaccine against Disease X
    • 14.3.11. Bavarian Nordic Launches Mpox Vaccine in the U.S., Boosting Preventive Healthcare and Market Innovation
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. AstraZeneca PLC
    • 14.4.2. Pfizer Inc.
    • 14.4.3. GlaxoSmithKline PLC
    • 14.4.4. Merck & Co., Inc.
    • 14.4.5. Sanofi S.A.

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Bavarian Nordic A/S
  • 5. Bharat Biotech Ltd.
  • 6. Biological E. Limited
  • 7. BioNTech SE
  • 8. Blue Lake Biotechnology
  • 9. Capricor Therapeutics, Inc.
  • 10. Chongqing Zhifei Biological Products Co., Ltd.
  • 11. CSL Limited
  • 12. CureVac N.V.
  • 13. Daiichi Sankyo Company, Limited.
  • 14. Emergent BioSolutions Inc.
  • 15. Gennova Biopharmaceuticals Limited
  • 16. GlaxoSmithKline PLC
  • 17. Haffkine Bio-Pharmaceutical Corporation Ltd
  • 18. Incepta Pharmaceuticals Ltd.
  • 19. Inovio Pharmaceuticals, Inc.
  • 20. Johnson & Johnson Services, Inc.
  • 21. Merck & Co., Inc.
  • 22. Moderna, Inc.
  • 23. Novavax, Inc.
  • 24. Pfizer Inc.
  • 25. Sanofi S.A.
  • 26. Serum Institute of India Pvt. Ltd.
  • 27. Sinovac Biotech Ltd.
  • 28. Takeda Pharmaceutical Company Limited
  • 29. VBI Vaccines Inc.
  • 30. Versatope Therapeutics
  • 31. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA (MRNA) VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINES MARKET SIZE, BY HAEMOPHILUS INFLUENZAE TYPE B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS A & HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY MEASLES, MUMPS, & RUBELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VACCINES MARKET SIZE, BY SHINGLES/HERPES ZOSTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINES MARKET SIZE, BY TETANUS, DIPHTHERIA, & PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. NORWAY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. POLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. QATAR VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. RUSSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SAUDI ARABIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SPAIN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWEDEN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. SWITZERLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. TURKEY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. UNITED KINGDOM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 245. VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 246. VACCINES MARKET, FPNV POSITIONING MATRIX, 2023